Oryzon Genomics KUV 2024

Mit csinál Oryzon Genomics?

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.